RP Cure Tracker

Trials / NCT01773278

Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)

Status unknown Phase 2 Supplement / diet, Drug / neuroprotection

Sponsor
University of Colorado, Denver
Treatment
Antioxidants; Cholesterol
Gene
Not stated
Conditions
Smith-Lemli-Opitz Syndrome, Cone-Rod Dystrophy, Hearing Loss
Ages
Any to 65 Years
Enrollment
100 participants
Started
2008-12
Main results expected
2025-12
Results posted
Not yet
Record last updated
2024-05-08

What the study is testing

Patients with biochemically confirmed SLOS are being treated with cholesterol supplementation and antioxidant medication. They are carefully monitored with visits to clinic, laboratory testing including cholesterol and 7-dehydrocholesterol levels, vitamin levels, blood counts and liver and kidney function. On a serial basis, no more often than once a year, the patients undergo a series of tests under anesthesia, including electroretinogram (ERG), brainstem audiometry (ABR), and ophthalmologic exam under anesthesia to follow pigmentary retinopathy.

Where it runs

United States (1)

Open on ClinicalTrials.gov for contacts and eligibility